Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis

Immunopharmacology and Immunotoxicology

Volumn 27, Issue 2, 2005, Pages 255-265

  Mirshafiey, Abbas ^a   Matsuo, Hidenori ^b   Nakane, Shunya ^b   Rehm, Bernd H A ^c   Koh, Chang Sung ^d   Miyoshi, Seiji ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c MASSEY UNIVERSITY   (New Zealand)

^d SHINSHU UNIVERSITY   (Japan)

Author keywords

Anti inflammatory; EAE; Immunosuppressive; M2000; Multiple sclerosis; NSAIDS

Indexed keywords

BETA MANNURONIC ACID; DEXAMETHASONE; DICLOFENAC; IMMUNOSUPPRESSIVE AGENT; M 2000; MYELIN BASIC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; STEROID; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HEXURONIC ACIDS; IMMUNIZATION; IMMUNOSUPPRESSIVE AGENTS; LYMPH NODES; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; MYELIN BASIC PROTEINS; RATS; RATS, INBRED LEW; TIME FACTORS;

ANIMALIA;

EID: 23244440434     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.1081/IPH-200067751     Document Type: Article

References (30)

1. Teuscher, C.; Bunn, J.Y.; Fillmore, P.D.; Butterfield, R.J.; Zachary, J.F.; Blankenhorn, E.P. Gender, age, and season at immunization uniquely influence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic encephalomyelitis: implications for the genetics of multiple sclerosis. Am. J. Pathol. 2004, 165, 1593-1602.
2. Andersson, A.; Karlsson, J. Genetics of experimental autoimmune encephalomyelitis in the mouse. Arch. Immunol. Ther. Exp. (Warsz). 2004, 52, 316-325.
3. Edan, G.; Morrissey, S.; Le Page, E. Rationale for the use of mitoxantrone in multiple sclerosis. J. Neurol. Sci. 2004, 223, 35-39.
4. Tanasescu, R.; Debouverie, M.; Pittion, S.; Anxionnat, R.; Vespignani, H. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J. Neurol. 2004, 251, 762-763.
5. Soos, N.; Shakery, K.; Mrowietz, U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (copaxone((r))) injection for the treatment of multiple sclerosis. Am. J. Clin. Dermatol. 2004, 5, 357-359.
6. Ziemssen, T.; Neuhaus, O.; Farina, C.; Hartung, H.P.; Hohlfeld, R. Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies. Nervenarzt 2002, 73, 321-331.
7. Simpson, D.; Noble, S.; Perry, C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs 2002, 16, 825-850.
8. Etheridge, L.J.; Beverley, D.W.; Ferrie, C.; McManus, E. The use of Interferon beta in relapsing-remitting multiple sclerosis. Arch. Dis. Child. 2004, 89, 789-791.
9. Billiau, A.; Kieseier, B.C.; Hartung, H.P. Biologic role of Interferon beta in multiple sclerosis. J. Neurol. 2004, 251, 10-14.
10. Lange-Asschenfeldt, C.; Boor, S.; Kahaly, G.J.; Thomke, F. Autoimmune functional disorders of the thyroid during interferon-beta-1b treatment in patients with multiple sclerosis. Case report and literature review. Nervenarzt 2004, 75, 589-594.
11. Deisenhammer, F.; Schellekens, H.; Bertolotto, A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J. Neurol. 2004, 251, 31-39.
12. Bertolotto, A.; Deisenhammer, F.; Gallo, P.; Solberg Sorensen, P. Immunogenicity of interferon beta: differences among products. J. Neurol. 2004, 251, II15-II24.
13. Pozzilli, C.; Marinelli, F.; Romano, S.; Bagnato, F. Corticosteroids treatment. J. Neurol. Sci. 2004, 223, 47-51.
14. Fernandez, O.; Fernandez, V.; De Ramon, E. Azathioprine and methotrexate in multiple sclerosis. J. Neurol. Sci. 2004, 223, 29-34.
15. Jeffery, D.R. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. J. Neurol. Sci. 2004, 223, 41-46.
16. Wiendl, H.; Hohlfeld, R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Bio. Drugs 2002, 16, 183-200.
17. Rio, J.; Montalban, X. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology 2000, 54, 1710.
18. Furlan, R.; Kurne, A.; Bergami, A.; Brambilla, E.; Maucci, R.; Gasparini, L.; Butti, E.; Comi, G.; Ongini, E.; Martino, G. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 150, 10-19.
19. Moon, C.; Ahn, M.; Jee, Y.; Heo, S.; Kim, S.; Kim, H.; Sim, K.B.; Koh, C.S.; Shin, Y.G.; Shin, T. Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci. Lett. 2004, 356, 123-126.
20. Reder, A.T.; Thapar, M.; Sapugay, A.M.; Jensen, M.A. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J. Neuroimmunol. 1994, 54, 117-127.
21. Ovadia, H.; Paterson, P.Y. Effect of indomethacin treatment upon actively-induced and transferred experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin. Exp. Immunol. 1982, 49, 386-392.
22. Loftis, J.M.; Hauser, P. The phenomenology and treatment of interferon-induced depression. J. Affect. Disord. 2004, 82, 175-190.
23. Matsuo, H.; Ichinose, K.; Ohtsuru, I.; Fujishita, S.; Onodera, H.; Suematsu, J.; Yoshida, M.; Yamawaki, N.; Shibuya, N. Treatment of experimental allergic encephalomyelitis by selective removal of CD4 T cells. Therap. Apher. 1997, 1, 165-168.
24. Muller, D.M.; Pender, M.P.; Greer, J.M. Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. Curr. Drugs, Targets Inflamm. Allergy 2004, 3, 279-290.
25. Hohlfeld, R.; Wekerle, H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 2004, 5, 14599-14606.
26. Giovannoni, G. Management of secondary-progressive multiple sclerosis. CNS Drugs 2004, 18, 653-669.
27. Adorini, L. Immunotherapeutic approaches in multiple sclerosis. J. Neurol. Sci. 2004, 223, 13-24.
28. Martin, R.; McFarland, H.F.; McFarlin, D.E. Immunological aspects of demyelinating disease. Annu. Rev. Immunol. 1992, 10, 153-187.
29. Frohman, E.M.; Brannon, K.; Racke, M.K.; Hawker, K. Mycophenolate mofetil in multiple sclerosis. Clin. Neuropharmacol. 2004, 27, 80-83.
30. Mirshafiey, A.; Khorramizadeh, M.R.; Saadat, F.; Rehm, B.H. Chemopreventive effect of M2000, a new anti-inflammatory agent. Med. Sci. Monit. 2004, 10, 105-109.